113 agrifood-climate companies failed between 2023-2026, destroying $18.5B in venture funding and proving the sector cannot survive on VC timelines

Between 2023 and early 2026, the agrifood and bio-industrial innovation sector experienced a financial collapse that killed 113 companies, wiped out approximately $18.5 billion in venture funding, and destroyed $31 billion in public market capitalization. This was not a gradual decline — it was a sector-wide extinction event. Cultivated meat funding fell from $989 million in 2021 to $55 million in 2024 and just $65 million in 2025. In the first nine months of 2025, cultivated meat startups received only $36 million total. Meatable (Netherlands, 100 employees), Believer Meats ($390M raised), CellRev (UK), Upstream Foods, and SCiFi Foods all ceased operations in 2025 alone. The consequence is not just the loss of individual companies — it is the loss of institutional knowledge, trained personnel, validated cell lines, proprietary processes, and years of R&D. When Meatable's key investor Agronomics wrote down its 11.9 million pound stake to zero, that was not just money disappearing; it was an entire research program on pluripotent stem cell differentiation for pork production being abandoned. When CellRev shut down, its proprietary media additives for cell manufacturing — potentially useful to every other cultivated meat company — went with it. The sector is not just losing capital; it is losing the accumulated technical infrastructure that would be needed to eventually succeed. This wave of failures reveals a structural mismatch between venture capital expectations and deep-tech biology timelines. VC funds operate on 7-10 year return cycles and expect portfolio companies to reach revenue milestones within 3-5 years of funding. Cultivated meat, precision fermentation, and novel protein technologies require 10-15 years of R&D, regulatory navigation, and infrastructure buildout before generating meaningful revenue. The 2021 funding peak was driven by climate-tech hype and low interest rates, not by realistic assessment of commercialization timelines. When interest rates rose and hype faded, VCs moved on to AI — but the biology did not get any faster. The surviving companies (Mosa Meat, Upside Foods, Aleph Farms) are now trying to build a capital-intensive manufacturing industry with a fraction of the funding their predecessors had, in an investor environment that views the entire sector as a failed experiment.